Sperling Prostate Center

Category: Active Surveillance

Statins and Prostate Cancer: An Update

Last December I posted a blog entry on the possibility that statins, a class of cholesterol-lowering drugs, can reduce the risk of developing aggressive prostate cancer (PCa). If you’re interested, I summarized the relationship between how statins control cholesterol and scientific theories about the connection with PCa; you can read it at https://sperlingprostatecenter.com/statins-prostate-cancer/. I try keep reading

What Happens When Prostate Biopsies Are Negative?

The annual American Urological Society meeting (AUA 2015, May 15-19) has more presentations than ever on multiparametric MRI detection of prostate cancer, MRI targeted biopsies, MRI/ultrasound fusion, and MRI-guided focal therapies. The urologic world is sitting up and taking notice as advanced imaging is changing the prostate cancer landscape. I will be sharing selected presentations keep reading

The Impact of the Recommendation Against PSA Screening

In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine PSA screening for otherwise healthy men. Almost immediately, prostate cancer support organizations and hundreds of clinical professionals raised an outcry. While acknowledging that the non-prostate cancer specific blood test often led to over-detection and over-treatment of indolent prostate cancer, countless lives keep reading
WordPress Image Lightbox